Dr. Reddy's Subsidiary Aurigene Opens Biologics Facility with Process Development and Clinical Scale Manufacturing Capabilities
Aurigene Pharmaceutical Services Limited, a step down wholly owned subsidiary of Dr. Reddy's Laboratories Ltd., has inaugurated a new biologics facility in Hyderabad, India. Spread across 70,000 sq.ft., the facility offers process development and clinical scale manufacturing capabilities for antibodies and other recombinant proteins. The facility, located in Genome Valley, a bio cluster, will ensure seamless transfer to large-scale commercial CGMP manufacturing facilities. The new capacity and capabilities demonstrate Dr. Reddy's commitment to expanding its biologics business, building on 25 years of proven experience. The state-of-the-art facility further strengthens Aurigene's capabilities in supporting customers 'end-to-end' from discovery services to large scale commercial manufacture of both Drug Substance and Drug Product.
Key Highlights
- Aurigene, a Dr. Reddy's Laboratories Limited company, inaugurated a new biologics facility in Hyderabad, India.
- The 70,000 sq.ft. facility offers process development and clinical scale manufacturing capabilities for antibodies and other recombinant proteins.
- The facility is designed to serve customers with process & analytical development and small scale manufacturing for preclinical and early phase clinical requirements.
- The new capacity and capabilities demonstrate Dr. Reddy's commitment to expanding its biologics business, building on 25 years of proven experience.
- The state-of-the-art facility further strengthens Aurigene's capabilities in supporting customers 'end-to-end' from discovery services to large scale commercial manufacture of both Drug Substance and Drug Product.